MicroRNAs in fatty liver disease

Seminars in Liver Disease

Volumn 35, Issue 1, 2015, Pages 12-25

  Sobolewski, Cyril ^a   Calo, Nicolas ^a   Portius, Dorothea ^a   Foti, Michelangelo ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

cirrhosis; fibrosis; noncoding RNA; steatohepatitis; steatosis

Indexed keywords

BIOLOGICAL MARKER; LIVER X RECEPTOR ALPHA; MICRORNA; MICRORNA 1; MICRORNA 107; MICRORNA 10B; MICRORNA 122; MICRORNA 128 2; MICRORNA 130A 3P; MICRORNA 155; MICRORNA 206; MICRORNA 21; MICRORNA 217; MICRORNA 24; MICRORNA 27; MICRORNA 27A; MICRORNA 27B; MICRORNA 30C; MICRORNA 33A; MICRORNA 33B; MICRORNA 34A; MICRORNA 613; MICRORNA 758; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CHOLESTEROL METABOLISM; DISEASE COURSE; FATTY ACID OXIDATION; FATTY LIVER; GENE EXPRESSION REGULATION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID TRANSPORT; LIPOGENESIS; LIPOPHAGOCYTOSIS; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER METABOLISM; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; REGULATORY RNA SEQUENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION; GENETICS; LIPID METABOLISM; LIVER; METABOLISM;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; FATTY LIVER; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; LIVER CIRRHOSIS; MICRORNAS; MOLECULAR TARGETED THERAPY;

EID: 84928543338     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1397345     Document Type: Article

References (155)

1. Altamirano J., Bataller R. Alcoholic liver disease: pathogenesis and new targets for therapy. Nat Rev Gastroenterol Hepatol: 2011; 8 9 491 501
2. Negro F. Hepatitis C virus-induced steatosis: an overview. Dig Dis: 2010; 28 1 294 299
3. Birkenfeld A. L., Shulman G. I. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology: 2014; 59 2 713 723
4. Bhala N., Jouness R. I., Bugianesi E. Epidemiology and natural history of patients with NAFLD. Curr Pharm Des: 2013; 19 29 5169 5176
5. Milić S., Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis: 2012; 30 2 158 162
6. Starley B. Q., Calcagno C. J., Harrison S. A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology: 2010; 51 5 1820 1832
7. Samuel V. T., Liu Z. X., Qu X., et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem: 2004; 279 31 32345 32353
8. Brown M. S., Goldstein J. L. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab: 2008; 7 2 95 96
9. Farese R. V. Jr, Zechner R., Newgard C. B., Walther T. C. The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. Cell Metab: 2012; 15 5 570 573
10. Tsochatzis E. A., Bosch J., Burroughs A. K. Liver cirrhosis. Lancet: 2014; 383 9930 1749 1761
11. Yates L. A., Norbury C. J., Gilbert R. J. The long and short of microRNA. Cell: 2013; 153 3 516 519
12. Bartel D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell: 2004; 116 2 281 297
13. Rayner K. J., Esau C. C., Hussain F. N., et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature: 2011; 478 7369 404 407
14. Patrick D. M., Montgomery R. L., Qi X., et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest: 2010; 120 11 3912 3916
15. Tay Y., Rinn J., Pandolfi P. P. The multilayered complexity of ceRNA crosstalk and competition. Nature: 2014; 505 7483 344 352
16. Young L. E., Moore A. E., Sokol L., Meisner-Kober N., Dixon D. A. The mRNA stability factor HuR inhibits microRNA-16 targeting of COX-2. Mol Cancer Res: 2012; 10 1 167 180
17. Horie T., Nishino T., Baba O., et al. MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice. Nat Commun: 2013; 4 2883
18. Ng R., Wu H., Xiao H., et al. Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia. Hepatology: 2014; 60 2 554 564
19. Szabo G., Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol: 2013; 10 9 542 552
20. Shibata C., Kishikawa T., Otsuka M., et al. Inhibition of microRNA122 decreases SREBP1 expression by modulating suppressor of cytokine signaling 3 expression. Biochem Biophys Res Commun: 2013; 438 1 230 235
21. Iliopoulos D., Drosatos K., Hiyama Y., Goldberg I. J., Zannis V. I. MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism. J Lipid Res: 2010; 51 6 1513 1523
22. Esau C., Davis S., Murray S. F., et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab: 2006; 3 2 87 98
23. Nie Y. Q., Cao J., Zhou Y. J., et al. The effect of miRNA-122 in regulating fat deposition in a cell line model. J Cell Biochem: 2014; 115 5 839 846
24. Li S., Chen X., Zhang H., et al. Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J Lipid Res: 2009; 50 9 1756 1765
25. Alisi A., Masotti A., Nobili V. Profiling microRNA expression: a snapshot of nonalcoholic steatohepatitis and a recording of its pathogenesis. Hepatology: 2009; 49 2 706 707
26. Trebicka J., Anadol E., Elfimova N., et al. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol: 2013; 58 2 234 239
27. Dippold R. P., Vadigepalli R., Gonye G. E., Patra B., Hoek J. B. Chronic ethanol feeding alters miRNA expression dynamics during liver regeneration. Alcohol Clin Exp Res: 2013; 37 01 E59 E69
28. Tsai W. C., Hsu S. D., Hsu C. S., et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest: 2012; 122 8 2884 2897
29. Hsu S. H., Wang B., Kota J., et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest: 2012; 122 8 2871 2883
30. Bhatia H., Verma G., Datta M. miR-107 orchestrates ER stress induction and lipid accumulation by post-transcriptional regulation of fatty acid synthase in hepatocytes. Biochim Biophys Acta: 2014; 1839 4 334 343
31. Xiao F., Yu J., Liu B., et al. A novel function of microRNA 130a-3p in hepatic insulin sensitivity and liver steatosis. Diabetes: 2014; 63 8 2631 2642
32. Geyeregger R., Zeyda M., Stulnig T. M. Liver X receptors in cardiovascular and metabolic disease. Cell Mol Life Sci: 2006; 63 5 524 539
33. Higuchi N., Kato M., Shundo Y., et al. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol Res: 2008; 38 11 1122 1129
34. Zhong D., Zhang Y., Zeng Y. J., et al. MicroRNA-613 represses lipogenesis in HepG2 cells by downregulating LXRα Lipids Health Dis: 2013; 12 32
35. Zhong D., Huang G., Zhang Y., et al. MicroRNA-1 and microRNA-206 suppress LXRα-induced lipogenesis in hepatocytes. Cell Signal: 2013; 25 6 1429 1437
36. Adlakha Y. K., Khanna S., Singh R., Singh V. P., Agrawal A., Saini N. Pro-apoptotic miRNA-128-2 modulates ABCA1, ABCG1 and RXRα expression and cholesterol homeostasis. Cell Death Dis: 2013; 4 e780
37. Miller A. M., Gilchrist D. S., Nijjar J., et al. MiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice. PLoS ONE: 2013; 8 8 e72324
38. Shirasaki T., Honda M., Shimakami T., et al. MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells. J Virol: 2013; 87 9 5270 5286
39. Peyrou M., Ramadori P., Bourgoin L., Foti M. PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs. PPAR Res: 2012; 2012 757803
40. Schadinger S. E., Bucher N. L., Schreiber B. M., Farmer S. R. PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol Endocrinol Metab: 2005; 288 6 E1195 E1205
41. Li X. SIRT1 and energy metabolism. Acta Biochim Biophys Sin (Shanghai): 2013; 45 1 51 60
42. Zhou B., Li C., Qi W., et al. Downregulation of miR-181a upregulates sirtuin-1 (SIRT1) and improves hepatic insulin sensitivity. Diabetologia: 2012; 55 7 2032 2043
43. Lee J., Padhye A., Sharma A., et al. A pathway involving farnesoid X receptor and small heterodimer partner positively regulates hepatic sirtuin 1 levels via microRNA-34a inhibition. J Biol Chem: 2010; 285 17 12604 12611
44. Yin H., Hu M., Zhang R., Shen Z., Flatow L., You M. MicroRNA-217 promotes ethanol-induced fat accumulation in hepatocytes by down-regulating SIRT1. J Biol Chem: 2012; 287 13 9817 9826
45. Dávalos A., Goedeke L., Smibert P., et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci U S A: 2011; 108 22 9232 9237
46. Zhang Y., Cheng X., Lu Z., et al. Upregulation of miR-15b in NAFLD models and in the serum of patients with fatty liver disease. Diabetes Res Clin Pract: 2013; 99 3 327 334
47. Koo S. H. Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis. Clin Mol Hepatol: 2013; 19 3 210 215
48. Ramirez C. M., Dávalos A., Goedeke L., et al. MicroRNA-758 regulates cholesterol efflux through posttranscriptional repression of ATP-binding cassette transporter A1. Arterioscler Thromb Vasc Biol: 2011; 31 11 2707 2714
49. Gerin I., Clerbaux L. A., Haumont O., et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem: 2010; 285 44 33652 33661
50. Goedeke L., Vales-Lara F. M., Fenstermaker M., et al. A regulatory role for microRNA 33∗ in controlling lipid metabolism gene expression. Mol Cell Biol: 2013; 33 11 2339 2352
51. Allen R. M., Marquart T. J., Albert C. J., et al. miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity. EMBO Mol Med: 2012; 4 9 882 895
52. Hoekstra M., van der Sluis R. J., Kuiper J., Van Berkel T. J. Nonalcoholic fatty liver disease is associated with an altered hepatocyte microRNA profile in LDL receptor knockout mice. J Nutr Biochem: 2012; 23 6 622 628
53. Kang M. H., Zhang L. H., Wijesekara N., et al. Regulation of ABCA1 protein expression and function in hepatic and pancreatic islet cells by miR-145. Arterioscler Thromb Vasc Biol: 2013; 33 12 2724 2732
54. Karagianni P., Talianidis I. Transcription factor networks regulating hepatic fatty acid metabolism. Biochim Biophys Acta: 2014;; (May): 9
55. Singaravelu R., Chen R., Lyn R. K., et al. Hepatitis C virus induced up-regulation of microRNA-27: a novel mechanism for hepatic steatosis. Hepatology: 2014; 59 1 98 108
56. Kida K., Nakajima M., Mohri T., et al. PPARα is regulated by miR-21 and miR-27b in human liver. Pharm Res: 2011; 28 10 2467 2476
57. Vinciguerra M., Sgroi A., Veyrat-Durebex C., Rubbia-Brandt L., Buhler L. H., Foti M. Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology: 2009; 49 4 1176 1184
58. Zheng L., Lv G. C., Sheng J., Yang Y. D. Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD. J Gastroenterol Hepatol: 2010; 25 1 156 163
59. Baroukh N., Ravier M. A., Loder M. K., et al. MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic beta-cell lines. J Biol Chem: 2007; 282 27 19575 19588
60. Ahn J., Lee H., Jung C. H., Ha T. Lycopene inhibits hepatic steatosis via microRNA-21-induced downregulation of fatty acid-binding protein 7 in mice fed a high-fat diet. Mol Nutr Food Res: 2012; 56 11 1665 1674
61. Vinciguerra M., Veyrat-Durebex C., Moukil M. A., Rubbia-Brandt L., Rohner-Jeanrenaud F., Foti M. PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF-kappaBp65/mTOR-dependent mechanism. Gastroenterology: 2008; 134 1 268 280
62. Berriot-Varoqueaux N., Aggerbeck L. P., Samson-Bouma M., Wetterau J. R. The role of the microsomal triglygeride transfer protein in abetalipoproteinemia. Annu Rev Nutr: 2000; 20 663 697
63. Tanoli T., Yue P., Yablonskiy D., Schonfeld G. Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity. J Lipid Res: 2004; 45 5 941 947
64. Soh J., Iqbal J., Queiroz J., Fernandez-Hernando C., Hussain M. M. MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat Med: 2013; 19 7 892 900
65. González-Rodríguez A., Mayoral R., Agra N., et al. Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD. Cell Death Dis: 2014; 5 e1179
66. Lin C. W., Zhang H., Li M., et al. Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice. J Hepatol: 2013; 58 5 993 999
67. Vescovo T., Romagnoli A., Perdomo A. B., et al. Autophagy protects cells from HCV-induced defects in lipid metabolism. Gastroenterology: 2012; 142 3 644 653.e3
68. Frankel L. B., Lund A. H. MicroRNA regulation of autophagy. Carcinogenesis: 2012; 33 11 2018 2025
69. Seca H., Lima R. T., Lopes-Rodrigues V., Guimaraes J. E., Almeida G. M., Vasconcelos M. H. Targeting miR-21 induces autophagy and chemosensitivity of leukemia cells. Curr Drug Targets: 2013; 14 10 1135 1143
70. Wang J., Yang K., Zhou L., et al. MicroRNA-155 promotes autophagy to eliminate intracellular mycobacteria by targeting Rheb. PLoS Pathog: 2013; 9 10 e1003697
71. Xu Y., An Y., Wang Y., et al. miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep: 2013; 29 5 2019 2024
72. Meng F., Glaser S. S., Francis H., et al. Epigenetic regulation of miR-34a expression in alcoholic liver injury. Am J Pathol: 2012; 181 3 804 817
73. Yang J., Chen D., He Y., et al. MiR-34 modulates Caenorhabditis elegans lifespan via repressing the autophagy gene atg9. Age (Dordr): 2013; 35 1 11 22
74. Shao W., Espenshade P. J. Expanding roles for SREBP in metabolism. Cell Metab: 2012; 16 4 414 419
75. Seo Y. K., Jeon T. I., Chong H. K., Biesinger J., Xie X., Osborne T. F. Genome-wide localization of SREBP-2 in hepatic chromatin predicts a role in autophagy. Cell Metab: 2011; 13 4 367 375
76. Samuel V. T., Shulman G. I. Mechanisms for insulin resistance: common threads and missing links. Cell: 2012; 148 5 852 871
77. Trajkovski M., Hausser J., Soutschek J., et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature: 2011; 474 7353 649 653
78. Yamamoto M., Toya Y., Schwencke C., Lisanti M. P., Myers M. G. Jr, Ishikawa Y. Caveolin is an activator of insulin receptor signaling. J Biol Chem: 1998; 273 41 26962 26968
79. Wang Y., Hu C., Cheng J., et al. MicroRNA-145 suppresses hepatocellular carcinoma by targeting IRS1 and its downstream Akt signaling. Biochem Biophys Res Commun: 2014; 446 4 1255 1260
80. Wen F., Yang Y., Jin D., Sun J., Yu X., Yang Z. MiRNA-145 is involved in the development of resistin-induced insulin resistance in HepG2 cells. Biochem Biophys Res Commun: 2014; 445 2 517 523
81. Ryu H. S., Park S. Y., Ma D., Zhang J., Lee W. The induction of microRNA targeting IRS-1 is involved in the development of insulin resistance under conditions of mitochondrial dysfunction in hepatocytes. PLoS ONE: 2011; 6 3 e17343
82. Pandey A. K., Verma G., Vig S., Srivastava S., Srivastava A. K., Datta M. miR-29a levels are elevated in the db/db mice liver and its overexpression leads to attenuation of insulin action on PEPCK gene expression in HepG2 cells. Mol Cell Endocrinol: 2011; 332 1-2 125 133
83. Leslie N. R., Foti M. Non-genomic loss of PTEN function in cancer: not in my genes. Trends Pharmacol Sci: 2011; 32 3 131 140
84. Jordan S. D., Krüger M., Willmes D. M., et al. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat Cell Biol: 2011; 13 4 434 446
85. Weber-Boyvat M., Zhong W., Yan D., Olkkonen V. M. Oxysterol-binding proteins: functions in cell regulation beyond lipid metabolism. Biochem Pharmacol: 2013; 86 1 89 95
86. Olivieri F., Rippo M. R., Procopio A. D., Fazioli F. Circulating inflamma-miRs in aging and age-related diseases. Front Genet: 2013; 4 121
87. McDaniel K., Herrera L., Zhou T., et al. The functional role of microRNAs in alcoholic liver injury. J Cell Mol Med: 2014; 18 2 197 207
88. Bala S., Marcos M., Kodys K., et al. Up-regulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor alpha (TNFalpha) production via increased mRNA half-life in alcoholic liver disease. J Biol Chem: 2011; 286 2 1436 1444
89. Jiang M., Broering R., Trippler M., et al. MicroRNA-155 controls Toll-like receptor 3- and hepatitis C virus-induced immune responses in the liver. J Viral Hepat: 2014; 21 2 99 110
90. Dolganiuc A., Petrasek J., Kodys K., et al. MicroRNA expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice. Alcohol Clin Exp Res: 2009; 33 10 1704 1710
91. Sarma N. J., Tiriveedhi V., Crippin J. S., Chapman W. C., Mohanakumar T. Hepatitis C virus-induced changes in microRNA 107 (miRNA-107) and miRNA-449a modulate CCL2 by targeting the interleukin-6 receptor complex in hepatitis. J Virol: 2014; 88 7 3733 3743
92. Cheung O., Puri P., Eicken C., et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology: 2008; 48 6 1810 1820
93. Wen J., Friedman J. R. miR-122 regulates hepatic lipid metabolism and tumor suppression. J Clin Invest: 2012; 122 8 2773 2776
94. Cazanave S. C., Mott J. L., Elmi N. A., et al. A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA. J Lipid Res: 2011; 52 8 1517 1525
95. Dooley S., ten Dijke P. TGF-β in progression of liver disease. Cell Tissue Res: 2012; 347 1 245 256
96. Friedman S. L. Mechanisms of hepatic fibrogenesis. Gastroenterology: 2008; 134 6 1655 1669
97. Miele L., Beale G., Patman G., et al. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology: 2008; 135 1 282 291.e1
98. Tu X., Zhang H., Zhang J., et al. MicroRNA-101 suppresses liver fibrosis by targeting the TGFβ signalling pathway. J Pathol: 2014; 234 1 46 59
99. Lakner A. M., Steuerwald N. M., Walling T. L., et al. Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology: 2012; 56 1 300 310
100. Guo C. J., Pan Q., Cheng T., Jiang B., Chen G. Y., Li D. G. Changes in microRNAs associated with hepatic stellate cell activation status identify signaling pathways. FEBS J: 2009; 276 18 5163 5176
101. He Y., Huang C., Sun X., Long X. R., Lv X. W., Li J. MicroRNA-146a modulates TGF-beta1-induced hepatic stellate cell proliferation by targeting SMAD4. Cell Signal: 2012; 24 10 1923 1930
102. Maubach G., Lim M. C., Chen J., Yang H., Zhuo L. miRNA studies in in vitro and in vivo activated hepatic stellate cells. World J Gastroenterol: 2011; 17 22 2748 2773
103. Marquez R. T., Bandyopadhyay S., Wendlandt E. B., et al. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest: 2010; 90 12 1727 1736
104. Zhang Z., Zha Y., Hu W., et al. The autoregulatory feedback loop of microRNA-21/programmed cell death protein 4/activation protein-1 (MiR-21/PDCD4/AP-1) as a driving force for hepatic fibrosis development. J Biol Chem: 2013; 288 52 37082 37093
105. Wang T., Zhang L., Shi C., et al. TGF-β-induced miR-21 negatively regulates the antiproliferative activity but has no effect on EMT of TGF-β in HaCaT cells. Int J Biochem Cell Biol: 2012; 44 2 366 376
106. Dey N., Ghosh-Choudhury N., Kasinath B. S., Choudhury G. G. TGFβ-stimulated microRNA-21 utilizes PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion. PLoS ONE: 2012; 7 8 e42316
107. Li Z. J., Ou-Yang P. H., Han X. P. Profibrotic effect of miR-33a with Akt activation in hepatic stellate cells. Cell Signal: 2014; 26 1 141 148
108. Iizuka M., Ogawa T., Enomoto M., et al. Induction of microRNA-214-5p in human and rodent liver fibrosis. Fibrogenesis Tissue Repair: 2012; 5 1 12
109. Wang B., Li W., Guo K., Xiao Y., Wang Y., Fan J. miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. Biochem Biophys Res Commun: 2012; 421 1 4 8
110. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S. T., Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology: 2007; 133 2 647 658
111. Takashima M., Parsons C. J., Ikejima K., Watanabe S., White E. S., Rippe R. A. The tumor suppressor protein PTEN inhibits rat hepatic stellate cell activation. J Gastroenterol: 2009; 44 8 847 855
112. Thum T., Gross C., Fiedler J., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature: 2008; 456 7224 980 984
113. Ji J., Zhang J., Huang G., Qian J., Wang X., Mei S. Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Lett: 2009; 583 4 759 766
114. Venugopal S. K., Jiang J., Kim T. H., et al. Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation. Am J Physiol Gastrointest Liver Physiol: 2010; 298 1 G101 G106
115. Mann J., Chu D. C., Maxwell A., et al. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology: 2010; 138 2 705 714, 714.e1-714.e4
116. Chen C., Wu C. Q., Zhang Z. Q., Yao D. K., Zhu L. Loss of expression of miR-335 is implicated in hepatic stellate cell migration and activation. Exp Cell Res: 2011; 317 12 1714 1725
117. Guo C. J., Pan Q., Jiang B., Chen G. Y., Li D. G. Effects of upregulated expression of microRNA-16 on biological properties of culture-activated hepatic stellate cells. Apoptosis: 2009; 14 11 1331 1340
118. Murakami Y., Toyoda H., Tanaka M., et al. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS ONE: 2011; 6 1 e16081
119. Roderburg C., Mollnow T., Bongaerts B., et al. Micro-RNA profiling in human serum reveals compartment-specific roles of miR-571 and miR-652 in liver cirrhosis. PLoS ONE: 2012; 7 3 e32999
120. Pogribny I. P., Starlard-Davenport A., Tryndyak V. P., et al. Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab Invest: 2010; 90 10 1437 1446
121. Li J., Ghazwani M., Zhang Y., et al. miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. J Hepatol: 2013; 58 3 522 528
122. Baffy G., Brunt E. M., Caldwell S. H. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol: 2012; 56 6 1384 1391
123. Farazi T. A., Hoell J. I., Morozov P., Tuschl T. MicroRNAs in human cancer. Adv Exp Med Biol: 2013; 774 1 20
124. Karakatsanis A., Papaconstantinou I., Gazouli M., Lyberopoulou A., Polymeneas G., Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog: 2013; 52 4 297 303
125. Cirera-Salinas D., Pauta M., Allen R. M., et al. Mir-33 regulates cell proliferation and cell cycle progression. Cell Cycle: 2012; 11 5 922 933
126. Coulouarn C., Factor V. M., Andersen J. B., Durkin M. E., Thorgeirsson S. S. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene: 2009; 28 40 3526 3536
127. Fujiyoshi M., Ozaki M. Molecular mechanisms of liver regeneration and protection for treatment of liver dysfunction and diseases. J Hepatobiliary Pancreat Sci: 2011; 18 1 13 22
128. Whittaker S., Marais R., Zhu A. X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene: 2010; 29 36 4989 5005
129. Creemers E. E., Tijsen A. J., Pinto Y. M. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res: 2012; 110 3 483 495
130. Ratajczak J., Wysoczynski M., Hayek F., Janowska-Wieczorek A., Ratajczak M. Z. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia: 2006; 20 9 1487 1495
131. Yamada H., Suzuki K., Ichino N., et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta: 2013; 424 99 103
132. Zhang X., Zhang Z., Dai F., et al. Comparison of circulating, hepatocyte specific messenger RNA and microRNA as biomarkers for chronic hepatitis B and C. PLoS ONE: 2014; 9 3 e92112
133. Wang K., Zhang S., Marzolf B., et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A: 2009; 106 11 4402 4407
134. Miyaaki H., Ichikawa T., Kamo Y., et al. Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int: 2014; 34 7 e302 e307
135. Tryndyak V. P., Latendresse J. R., Montgomery B., et al. Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet. Toxicol Appl Pharmacol: 2012; 262 1 52 59
136. Dubin P. H., Yuan H., Devine R. K., Hynan L. S., Jain M. K., Lee W. M.; Acute Liver Failure Study Group. Micro-RNA-122 levels in acute liver failure and chronic hepatitis C. J Med Virol: 2014; 86 9 1507 1514
137. Cermelli S., Ruggieri A., Marrero J. A., Ioannou G. N., Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS ONE: 2011; 6 8 e23937
138. Chen Y. P., Jin X., Xiang Z., Chen S. H., Li Y. M. Circulating MicroRNAs as potential biomarkers for alcoholic steatohepatitis. Liver Int: 2013; 33 8 1257 1265
139. Bala S., Petrasek J., Mundkur S., et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology: 2012; 56 5 1946 1957
140. Ogawa T., Enomoto M., Fujii H., et al. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut: 2012; 61 11 1600 1609
141. Zhang Y., Liu D., Chen X., et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell: 2010; 39 1 133 144
142. Ismail N., Wang Y., Dakhlallah D., et al. Macrophage microvesicles induce macrophage differentiation and miR-223 transfer. Blood: 2013; 121 6 984 995
143. Stenvang J., Petri A., Lindow M., Obad S., Kauppinen S. Inhibition of microRNA function by antimiR oligonucleotides. Silence: 2012; 3 1 1
144. Wang X., Yu B., Ren W., et al. Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations. J Control Release: 2013; 172 3 690 698
145. Hu J., Xu Y., Hao J., Wang S., Li C., Meng S. MiR-122 in hepatic function and liver diseases. Protein Cell: 2012; 3 5 364 371
146. Janssen H. L., Reesink H. W., Lawitz E. J., et al. Treatment of HCV infection by targeting microRNA. N Engl J Med: 2013; 368 18 1685 1694
147. Rayner K. J., Suárez Y., Dávalos A., et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science: 2010; 328 (5985): 1570 1573
148. Sayed D., Rane S., Lypowy J., et al. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol Biol Cell: 2008; 19 8 3272 3282
149. Szabo G., Sarnow P., Bala S. MicroRNA silencing and the development of novel therapies for liver disease. J Hepatol: 2012; 57 2 462 466
150. Tillman L. G., Geary R. S., Hardee G. E. Oral delivery of antisense oligonucleotides in man. J Pharm Sci: 2008; 97 1 225 236
151. Friedman R. C., Farh K. K., Burge C. B., Bartel D. P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res: 2009; 19 1 92 105
152. Choi S. E., Fu T., Seok S., et al. Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT. Aging Cell: 2013; 12 6 1062 1072
153. Derdak Z., Villegas K. A., Harb R., Wu A. M., Sousa A., Wands J. R. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J Hepatol: 2013; 58 4 785 791
154. Krutzfeldt J., Rajewsky N., Braich R., et al. Silencing of microRNAs in vivo with antagomirs Nature: 2005; 438 7068 685 689
155. Chen Y. J., Zhu J. M., Wu H., et al. Circulating microRNAs as a fingerprint for liver cirrhosis. PloS ONE: 2013; 8 6 e66577